anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to polymeric salts of 3,5-dimethyl-1-adamantyl-ammonium and of carboxyl-containing (co) polymers and to the use of the thus obtained salts in the form of antiviral agents. The aim of said invention is to synthesise the novel salts of 3,5-dimethyl-1-adamantyl-ammonium and of carboxyl-containing (co) polymers and in selecting thereamong compounds exhibiting an antiviral activity and durable action. Said aim is achieved by synthesising the 3,5-dimethyl-1-adamantyl-ammonium salts and water-soluble carboxyl-containing (co) polymers of general formula (1), wherein m and n are mol. %, m=100-n, the carboxyl-containing (co) polymers are selected from a group of polyvinyl-amino-succinic acid, vinyl alcohol and N-vinyl-amino-succinic acid copolymer, N-vinyl-pyrrolidone and N-vinyl-amino-succinic acid copolymer, N-vinyl-pyrrolidone and crotonic acid copolymer, N-vinyl-succinimide and maleinic anhydride copolymer, N-vinyl-pyrrolidone and maleinic anhydride copolymer and polyacrylic acid. A general synthesis method and synthesis examples for each inventive compound, toxicity test results and results of determination of the comparative antiviral activity are also disclosed. The obtained compounds are uniquely identifiable by IR-spectroscopy methods, element analysis and potentiometric titrimetric analysis, exhibit a sufficiently high antiviral activity with respect to A-type and B-type influenza viruses, they are characterised by a long (durable) activity, thereby making it possible to use the obtained salts not only as antiviral agents for sparing therapy but also for preventing viral diseases.
To treat the enrolled patients with oral rapamycin at an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
The invention relates to a non-oxidative permanent type natural melanoid hair water and a preparation method thereof. The melanoid hair water is prepared with natural materials and is formed by No. 1 hair dye and No. 2 hair dye. The No. 1 hair dye takes clove as an osmotic agent, takes cysteine as a reducing agent, takes nutgall, myrobalan and gallnut as the paints and takes angelica as a nutrition component; the No. 2 hair dye takes copperas as a visualization reagent and leads the copperas to be aggregated with the dye component of the No. 1 hair dye into a black paint giant molecule. The invention, on the basis of the application of a traditional Chinese medicine osmotic agent, also applies a natural reducing agent of the cysteine to cut off a hair keratin disulfide and increase the hair fasciola clearances, to lead the traditional Chinese medicine paint molecule to be easier to enter the hair fasciola clearances and lead the melanoid hair to be blacker and firmer; while the hair dye is easy to wash when contacting the scurf and can be used only by heating for one time. The invention is easyto be accepted by more consumers.
Rituximab-abbs is a monoclonal antibody. Rituximab products target the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab products mediate B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production.
Cerebral AVM are defined by abnormal connections between arteries and veins. For treatment of this vascular malformation, embolization is the gold standard. Embolization agent is made with vinylic alcohol ethylene (EVOH) copolymer which (the embolization implant) and the DMSO which is the solvent. During the injection of the product, DMSO dissipates in the bloodstream, and the EVOH precipitates and forms the embolus. It knows that DMSO had in-vitro immune effect (inhibits signalizations ways of innate and acquired immune response, decrease of pro-inflammatory cytokines production and decrease INF-γ and TNF-α production). DMSO could decrease activation and recruitment of leukocytes, which could expose patients to an increased risk of infection.

The investigator will dose cytokines in 3 blood samples (preoperative, H+6 and H+24) in planned patient's hospitalized for cerebral AVM embolization. The cytokine content of the plasmas will be analyzed with multiplex ELISA technic
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumour cells.
The proposed study is a randomized clinical trial with a wait-list control. The sample will be 60 HIV+ young adults between the ages of 16 to 24 years recruited from the DMC Horizons Project and other community based HIV programs. Self referred persons meeting the diagnostic criteria of HIV+ will also be accepted. There are no exclusion criteria. Subjects will be randomly assigned to one of 2 groups: MET NOW or MET LATER. MET LATER is the wait list control group. The only difference between the groups is the timing of the intervention and data collection. All subjects will complete 5 research visits and 4 MET therapy sessions. Research visits consists of an interview, completion of self-report questionnaires, a 20cc blood drawn for complete blood count (CBC), viral load and CD4 count, and adherence rating completed by the physician. Established questionnaires are used to measure health behaviors, sexual risk behaviors, substance use, self-efficacy, stage of change, social support, health beliefs, and mental health status. Research visits take about 1 = hours. Therapy sessions consist of MET provided by a trained therapist. Sessions last about 1 hour and focus on changing behavior to improve health, increase medical adherence, and/or reduce risk. Subjects choose the behaviors they want to change. There are a total of 4 sessions over 3 months. The MET NOW group will begin session immediately after the first (baseline) research visit and the MET LATER group will begin therapy sessions approximately 9 months after the first research visit. All subjects will be paid $25.00 for the first research visit with a $5 increase for each subsequent research visit, a total of $175.00 for the 5 research visits. Subjects will receive $10 gift certificate at each therapy session. Cab vouchers or parking fees will be provided for each therapy or research session.
BACKGROUND: The diagnosis of supernumerary X & Y chromosome variations has increased following the implementation of genetic testing in pediatric practice. Empirical evidence suggests that the delivery of the diagnosis has a lasting impact on how affected individuals and their parents perceive and adapt to the diagnosis. The purpose of this review is to synthesize the literature to obtain useful recommendations for delivering a pediatric diagnosis of a sex chromosome multisomy (SCM) based upon a growing body of quantitative and qualitative literature on patient experiences.
METHODS: We conducted an integrative literature review using PubMed, Web of Science and CINAHL employing keywords "genetic diagnosis delivery," "genetic diagnosis disclosure," "sex chromosome aneuploidy," "Klinefelter syndrome" or ""47, XXY," "Jacob syndrome" or "47, XYY," "Trisomy X," "Triple X" or "47, XXX," and "48 XXYY from January 1, 2000, to October 31, 2023.
RESULTS: Literature supports that patients and parents value the provision of up-to-date information and connection with supportive resources. Discussion of next steps of care, including relevant referrals, prevents perceptions of provider abandonment and commitment to ongoing support. Proactively addressing special concerns such as disclosing the diagnosis to their child, family, and community is also beneficial. Tables are provided for useful information resources, medical specialties that may be required to support patients, and common misconceptions that interfere with accurate information about the diagnosis.
CONCLUSION: Patient experiences suggest there should be heightened attention to diagnosis delivery, in reference to the broader ethical and social impacts of a SCM diagnosis. We present recommendations for optimal disclosure of a SCM diagnosis in early and late childhood, adolescence, and young adulthood.
The invention relates to a recombinant bifidobacterium hRV-VP7 expression vector and the oral vaccine. The invention pertains to the field of genetic engineering. The technical problem to be solved is to construct a new bifidobacterium expression vector of hRV virus VP7 protein. The recombinant bifidobacterium hRV-VP7 expression vector of the invention is loaded with a virus protein VP7 coding gene sequence of a human group A rotavirus. The expression vector of the invention can be transfected into the bifidobacterium and can be further prepared into an hRV/VP7 transgenic bifidobacterium-hRV-VP7 recombinant vector oral live vaccine preparation after fermentation culture. The invention is mainly used for the prevention and adjuvant treatment of infantile diarrhea which is caused by human rotavirus, thus having great market prospect.
The diagnostic potential of paramagnetic rim lesions (PRLs) has been previously established; however, the prognostic significance of these lesions has not previously been consistently described. This study aimed to establish the prognostic role of PRLs in MS with respect to the Expanded Disability Status Scale (EDSS) and rates of disability progression. Databases of PubMed, EMBASE, Scopus and reference lists of selected articles were searched up to 29/04/2023. The review was conducted in accordance with PRISMA guidelines and was registered prospectively on PROSPERO (CRD42023422052). 7 studies were included in the final review. All of the eligible studies found that patients with PRLs tend to have higher baseline EDSS scores. Longitudinal assessments revealed greater EDSS progression in patients with PRLs over time in most studies. However, the effect of location of PRLs within the central nervous system were not assessed across the studies. Only one study investigated progression independent of relapse activity (PIRA) and showed that this clinical entity occurred in a greater proportion in patients with PRLs. This review supports PRLs as a predictor of EDSS progression. This measure has widespread applicability, however further multicentre studies are needed. Future research should explore the impact of PRLs on silent disability, PIRA, take into account different MS phenotypes and the topography of PRLs in prognosis.
The invention relates to a Chinese medicine composition for activating blood and stopping pain and for treating chronic lumbar strain, a preparation process and application. The Chinese medicine composition is characterized by being composed of the following raw material medicines by weight: rehmannia glutinosa 28-32 parts, caulis spatholobi 12-18 parts, angelica sinensis 8-12 parts, achyranthes bidentata 8-12 parts, liquorice 4-6 parts, longspur epimedium 8-12 parts, teasel root 12-18 parts, frankincense 4-6 parts, fructus psoraleae 8-12 parts, desert living cistanche 8-12 parts, xuanhu 8-12 parts, bark of eucommia 12-18 parts, radix pseudostellariae 18-22 parts, borneol 3-5 parts and ground beeltle 4-12 parts. The preparation process comprises taking the borneol and the ground beeltle with the parts, and respectively crushing the borneol and the ground beeltle into fine powder; performing ethanol extraction on the other medicines to obtain ethanol extract fine powder; and evenly mixing the obtained objects. A plurality of medicines are combined for use to achieve the effects of jointly nourishing and activating blood, tonifying kidneys and strengthening tendon. The Chinese medicine composition for activating the blood and stopping the pain, the preparation process and the application are used for treating diseases of chronic lumbar strain and the like caused by kidney and liver insufficiency and qi and blood weakness. The total effective rate is 97.1%.
The subjects fasted overnight for at least 10 hours, and an indwelling needle was buried before administration. On the morning of administration, one test formulation (T) or one control formulation (R) was administered on an empty stomach, and the start time of administration was recorded. After administration, the oral cavity and medication container should be checked to ensure the correct use of the medication. Do not drink water from 1 hour before medication to 1 hour after medication (except for 20ml of water moistened with the test formulation and 240 mL of water from the control formulation). Control drinking water from 1 hour to 4 hours after medication, and drink freely at other times. Fasting within 4 hours after medication. After medication, keep the upper body upright for 4 hours. The meal time on the day of the two cycles of medication is roughly the same.
<P>PROBLEM TO BE SOLVED: To make expensive special medicines and the treatment by doctors unnecessary, which have been conventionally required for therapy of tooth gum swelling, pyorrhoea alveolaris, decayed tooth, halitosis, stomatitis, lingual cancer, throat cancer, common cold and the like.  <P>SOLUTION: The prevention and therapy can be performed by each individual in his home, easily, simply and at a low cost. A liquid obtained by mixing a liquid (1) corresponding to water, a liquid (2) containing salt or a salinity component, and, in some cases, a halitosis preventive (5), is prepared. In the liquid, chlorine ion and sodium ion coexist in the state that they are enclosed with hydrogen and oxygen of water molecules, and separated. The chlorine ion enclosed with hydrogen of the water molecule has germicidal action. And, when coming into contact with someone, good smell is generated by action of the halitosis preventive (5), so that good impression is presented to him. By using the liquid, the teeth are polished and the mouth is washed and gargled, directly.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing a sleeve gastrectomy (SG). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
BACKGROUND: Sexually transmitted infections (STIs), particularly in the absence of viral suppression, increase the risk of HIV transmission to uninfected partners. We determined factors associated with having an unsuppressed VL among HIV-positive individuals attending STI services in South Africa (SA).
METHODS: We analysed secondary cross-sectional data collected on HIV-positive individuals presenting with STI symptoms s at sentinel sites in Western Cape and Gauteng provinces between January-December 2019 in SA. We compared demographic characteristics of individuals on ART or not on ART, and a Poisson regression model to identify factors associated with having an unsuppressed VL (≥ 50 copies/ml) was used.
RESULTS: Among 93 HIV-positive individuals attending STI services with VL data, the median age was 32 years (IQR 27-37). Thirty-two (34.41%) individuals were on ART compared to 61 (65.59%) not on ART. Most of those on ART (56.25%) had an unsuppressed VL, while 86.89% of those not on ART had an unsuppressed VL. ART use was associated with a 33% lower prevalence of having unsuppressed VL. In a model adjusting for age, age at first sex and oral sex, none of the factors were significant. Among those on ART, individuals < 25 years were more likely to have an unsuppressed VL (aPRR = 1.94: 95% CI = 1.27-2.97) compared to those ≥ 25 years.
CONCLUSION: ART use among HIV-positive individuals was low and VL suppression among those on ART was sub-optimal. Intensified ART initiation and adherence support to HIV-positive individuals seeking STI services could improve VL suppression.
The invention belongs to a traditional Chinese medicine and especially relates to a traditional Chinese medicine for treating simple tuberculosis. The traditional Chinese medicine is characterized by comprising 180-220g of bighead atractylodes rhizome, 80-120g of pilose asiabell root, 80-120g of honeysuckle flower, 50-70g of Chinese angelica, 50-70g of licorice, 50-70g of coptis and 800-1200g of bee sugar. The bighead atractylodes rhizome, pilose asiabell root, honeysuckle flower, Chinese angelica, licorice and coptis are grinded into powder and the powder is mixed uniformly and then is added with the bee sugar and the mixture is processed into 60 granules. The two granules are taken with boiled water after a meal respectively in the morning and in the evening every day. Through use of the traditional Chinese medicine for 2-6 months, simple tuberculosis can be cured. The traditional Chinese medicine is designed according to the traditional Chinese medicine differentiation theory, has a simple formula, utilizes the easily acquired raw materials, and has a low cost, high curative effects and no toxic or side effect, and can adjust the human body to a normal state.
BACKGROUND: The 2020 cancer report states that breast cancer remains a significant cause of death for females, despite the use of various strategies for early detection and treatment. However, there are still gaps in the fight against this disease. Researchers are exploring the hippo pathway, one of eight significant pathways involved in cancer progression, for potential biomarkers to use in personalized therapeutics.
METHODS: The current study used bioinformatic tools such as DEGs analysis, Methsurv, Km Plotter to generate data that can predict molecular biomarkers associated with hippo pathway in breast cancer development and treatment. The protein-protein interaction pathway was generated using the STRING database to find associations of hippo pathway genes with other dysregulated genes in breast cancer datasets. A disease enrichment study was also done to explore the potential of the hippo pathway in various aspects.
RESULTS: LATS2 and FAT4 genes of the hippo pathway have shown an interesting association with overall survival, hypermethylation, genetic alterations, and decreased expression levels in the breast cancer cohort. Our findings suggest that both of these genes are associated with breast cancer progression and diagnosis and can be utilized as predictive biomarkers by oncologists for personalized therapy in patients.
Sepsis frequently causes systemic inflammatory response syndrome and multiple organ failure in patients. Neoastilbin (NAS) is a flavonoid that plays vital functions in inflammation. This work aims to investigate the protective effects of NAS against sepsis-induced liver and kidney injury and elucidate its underlying mechanisms. The mouse model was established using cecal ligation puncture (CLP) induction. NAS was given to mice by gavage for 7 consecutive days before surgery. Liver and kidney function, oxidative stress, and inflammatory factors in serum or tissues were examined by ELISA or related kits. The expression of relevant proteins was assessed by Western blot. Hematoxylin and eosin and/or periodic acid-Schiff staining revealed that NAS ameliorated the pathological damage in liver and kidney tissues of CLP-induced mice. NAS improved liver and kidney functions, as evidenced by elevated levels of blood urea nitrogen, Creatinine, ALT, and AST in the serum of septic mice. TUNEL assay and the expression of Bcl-2 and Bax showed that NAS dramatically reduced apoptosis in liver and renal tissues. NAS treatment lowered the levels of myeloperoxidase and malondialdehyde, while elevated the superoxide dismutase content in liver and kidney tissues of CLP-induced mice. The levels of inflammatory cytokines (IL-6, TNF-α, and IL-1β) in the serum and both tissues of CLP-injured mice were markedly decreased by NAS. Mechanically, NAS downregulated TLR4 expression and inhibited NF-κB activation, and overexpression of TLR4 reversed the protective effects of NAS against liver and kidney injury. Collectively, NAS attenuated CLP-induced apoptosis, oxidative stress, inflammation, and dysfunction in the liver and kidney by restraining the TLR4/NF-κB pathway.
BACKGROUND AND OBJECTIVE: Myofascial pain syndrome (MPS) is a chronic musculoskeletal disorder characterized by the presence of trigger points. Among the treatment options, botulinum toxin injections have been investigated. The aim of this paper was to provide a synthesis of the evidence on intramuscular botulinum toxin injections for upper back MPS.
DATABASES AND DATA TREATMENT: A systematic review of the literature was performed on the PubMed, Scopus and Cochrane Library, using the following formula: ("botulinum") AND ("musculoskeletal") AND ("upper back pain") OR ("myofascial pain").
RESULTS: Ten studies involving 651 patients were included. Patients in the control groups received placebo (saline solution) injections, anaesthetic injections + dry needling or anaesthetic injections. The analysis of the trials revealed modest methodological quality: one "Good quality" study, one "Fair" and the other "Poor". No major complications or serious adverse events were reported. Results provided conflicting evidence and did not demonstrate the superiority of botulinum toxin over comparators. Most of the included trials were characterized by a small sample size, weak power analysis, different clinical scores used and non-comparable follow-up periods. Even if there is no conclusive evidence, the favourable safety profile and the positive results of some secondary endpoints suggest a potentially beneficial action in pain control and quality of life.
CONCLUSION: The currently available studies show conflicting results. Their overall low methodological quality does not allow for solid evidence of superiority over other comparison treatments. Further insights are needed to properly profile patients who could benefit more from this peculiar injective approach.
SIGNIFICANCE: The randomized controlled trials included in this review compared using botulinum toxin to treat upper back MPS with placebo or active treatments (e.g., dry needling or anaesthetics) showing mixed results overall. Despite the lack of clear evidence of superiority, our study suggests that the use of botulinum toxin should not be discouraged. Its safety profile and encouraging results in pain control, motor recovery and disability reduction make it an interesting treatment, particularly in the subset of patients with moderate to severe chronic pain and active trigger points. To support the safety and efficacy of botulinum toxin, further high-quality studies are needed.